Protein / target
Inosine-5'-monophosphate dehydrogenase 1
Protein at a glance
Biological role
IMP dehydrogenase
Strongest disease association
Retinitis pigmentosa 10
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.
View complete UniProt function annotationHide complete annotation
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors
Subcellular location
Domains and Gene Ontology detail (19)Hide
Domains & features
Gene Ontology
- Cazurophil granule lumen
- Ccytoplasm
- Ccytosol
- Cextracellular region
- Cficolin-1-rich granule lumen
- Cnucleus
- Csecretory granule lumen
- FDNA binding
- Fidentical protein binding
- FIMP dehydrogenase activity
- Fmetal ion binding
- Fnucleic acid binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
8 medicines meet Open Targets' target-level approved-medicine definition; the 4 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Inosine-5'-monophosphate dehydrogenase 1 inhibitor
Indicated for Fibrosis, Hepatitis C, Chronic, Liver Cirrhosis, Virus Diseases
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Indicated for Immune System Diseases
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Indicated for Delayed Graft Function
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Indicated for Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene IMPDH1
Gene-level evidence surfaced through the gene IMPDH1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
9 compounds recorded · 8 approved · 1 in clinical development
View all recorded compounds (9)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Product recall
Recall (Class II): MYCOPHENOLATE MOFETIL
- Trial status changed
A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)
- Supplemental approval
Supplemental approval: MYCOPHENILIC ACID (ANDA091248)
- Supplemental approval
Supplemental approval: MYCOPHENOLATE MOFETIL (ANDA065379)
- Supplemental approval
Supplemental approval: MYCOPHENOLATE MOFETIL (ANDA065410)
- Product recall
Recall (Class II): MYCOPHENOLATE MOFETIL
- Regulatory approval
Approval: MYCOPHENOLATE MOFETIL (ANDA218566)
- New publicationSafety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
- New publicationSofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
- Safety communication
Drug Safety Update: Mycophenolate mofetil: pure red cell aplasia
- New publicationSofosbuvir and ribavirin in HCV genotypes 2 and 3.
- New publicationRetreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.